types of diabetes and treatment
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive, high-quality content from multiple authoritative textbooks. Here is a thorough overview:
Diabetes Mellitus: Types and Treatment
Classification
Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
Type 1 Diabetes Mellitus (T1DM)
An autoimmune condition in which immune-mediated destruction of pancreatic β cells leads to an absolute deficiency of insulin. Patients are dependent on exogenous insulin for survival. Without treatment, severe hyperglycemia and diabetic ketoacidosis (DKA) ensue. Though classically presenting in childhood, it can occur at any age.
Type 2 Diabetes Mellitus (T2DM)
The most common form (~90–95% of all diabetes). Caused by a combination of:
- Impaired insulin secretion — by the time of diagnosis, up to 50% of β-cell mass may have failed
- Insulin resistance — tissues (liver, muscle, adipose) fail to respond appropriately to insulin
Hyperglycemia is initially mild and asymptomatic for years. Classic symptoms (polyuria, polydipsia, weight loss) appear only when plasma glucose exceeds the renal threshold (~180–200 mg/dL). Obesity — especially abdominal obesity — is the single most important clinical predictor.
Gestational Diabetes
Glucose intolerance first recognized during pregnancy, due to placental hormones inducing insulin resistance.
Other Specific Types
- Monogenic diabetes (MODY — maturity-onset diabetes of the young): single gene defects in β-cell function
- Secondary diabetes: pancreatitis, hemochromatosis, Cushing syndrome, acromegaly, drug-induced (e.g., corticosteroids, antipsychotics)
Diagnostic Criteria
| Test | Diabetes | Prediabetes |
|---|---|---|
| Fasting plasma glucose | ≥126 mg/dL | 100–125 mg/dL |
| 2-hour OGTT | ≥200 mg/dL | 140–199 mg/dL |
| HbA1c | ≥6.5% | 5.7–6.4% |
| Random glucose + symptoms | ≥200 mg/dL | — |
Treatment
Glycemic Targets
The ADA recommends a target HbA1c ≤7% (mean glucose ≤154 mg/dL) for most patients. HbA1c should be measured twice yearly in stable patients and quarterly when therapy is changed or targets not met.
Type 1 Diabetes: Treatment
Insulin is the only treatment for type 1 diabetes.
Insulin Preparations
| Type | Examples | Onset | Duration | Use |
|---|---|---|---|---|
| Rapid-acting | Lispro, Aspart, Glulisine | 15–30 min | 3–5 hrs | Mealtime (prandial) control |
| Short-acting | Regular insulin | 30 min | 6–10 hrs | Mealtime; IV use |
| Intermediate-acting | NPH (Isophane) | 1–2 hrs | 12–18 hrs | Basal control |
| Long-acting | Glargine, Detemir, Degludec | 1–4 hrs | 20–24+ hrs | Once-daily basal |
| Inhaled | Inhaled insulin | 10–20 min (peak) | Short | Rapid prandial option |
Intensive vs. Standard Insulin Therapy
- Standard: two daily injections
- Intensive: three or more injections daily with frequent glucose monitoring
Intensive therapy achieves the ADA HbA1c target more reliably and significantly reduces microvascular complications (retinopathy, nephropathy, neuropathy), but increases the risk of hypoglycemic episodes. It is not recommended for patients with advanced age, long-standing disease, significant complications, or hypoglycemia unawareness.
Type 2 Diabetes: Treatment
Treatment is stepwise, starting with lifestyle modification and adding pharmacotherapy as needed.
1. Lifestyle Modification (Foundation of Treatment)
- Diet: Mediterranean, DASH, or vegetarian diets are effective. Moderate carbohydrate intake; avoid concentrated sweets and saturated fats. A registered dietitian with quarterly follow-up is recommended.
- Exercise: ≥150 min/week of moderate-to-vigorous aerobic activity. Walking ≥30 min/day improves insulin sensitivity and glycemic control.
- Weight loss: Even 5–10% body weight reduction meaningfully improves glycemic control.
2. Non-Insulin Pharmacotherapy
Biguanides — Metformin (first-line)
Decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity. Usually the first drug added. Main adverse effects: GI symptoms (nausea, diarrhea). Rare but serious: lactic acidosis. Contraindicated in severe renal impairment.
Sulfonylureas (e.g., Glipizide, Glyburide, Glimepiride)
Stimulate insulin secretion from β cells. Effective but associated with hypoglycemia and weight gain. Should not be combined with meglitinides (overlapping mechanism).
Meglitinides (e.g., Repaglinide, Nateglinide)
Rapid-onset insulin secretagogues; taken before meals to control postprandial glucose. Lower hypoglycemia risk than sulfonylureas. Metabolized by CYP enzymes; concurrent gemfibrozil with repaglinide is contraindicated.
Thiazolidinediones / TZDs (e.g., Pioglitazone)
PPARγ agonists — increase insulin sensitivity in adipose tissue, liver, and muscle. Do not cause hypoglycemia alone. Adverse effects: fluid retention (avoid in heart failure), weight gain, fracture risk, possible bladder cancer risk (pioglitazone). Rosiglitazone carries a boxed warning for cardiovascular risk.
DPP-4 Inhibitors (e.g., Sitagliptin, Saxagliptin)
Inhibit degradation of GLP-1 and GIP, enhancing glucose-dependent insulin secretion. Weight-neutral. Low hypoglycemia risk. Generally well tolerated.
SGLT-2 Inhibitors (e.g., Empagliflozin, Dapagliflozin, Canagliflozin)
Block glucose reabsorption in the kidney, increasing urinary glucose excretion. Reduce HbA1c, weight, and blood pressure. Empagliflozin and dapagliflozin have proven cardiovascular and renal protective benefits. Adverse effects: genital yeast infections, UTIs, risk of DKA (avoid with very-low-carbohydrate diets).
GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide, Dulaglutide, Exenatide)
Mimic incretin hormones — stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and promote satiety → weight loss. Semaglutide, liraglutide, and dulaglutide reduce cardiovascular mortality in high-risk patients. Injectable (semaglutide also available orally). Adverse effects: nausea, vomiting.
Alpha-Glucosidase Inhibitors (e.g., Acarbose)
Delay carbohydrate absorption in the gut → reduce postprandial hyperglycemia. GI side effects (flatulence, bloating) are common. Must use glucose (not sucrose) to treat hypoglycemia.
Amylin Analog — Pramlintide
Synthetic amylin analog used as adjunct to mealtime insulin in both T1DM and T2DM. Delays gastric emptying, reduces postprandial glucagon, improves satiety. Reduce mealtime insulin dose by 50% when initiating. Contraindicated in gastroparesis.
3. Insulin in Type 2 Diabetes
Insulin is reserved for when oral agents fail or are insufficient, though it can be used at any stage. As β-cell failure progresses, many T2DM patients eventually require insulin. Short-term intensive insulin (2 weeks to 3 months) is also used when HbA1c is ≥9% at diagnosis with symptomatic hyperglycemia. Concentrated insulin formulations (U-200, U-300, U-500) are available for highly insulin-resistant patients requiring >100 units/day.
4. Bariatric Surgery
For patients with severe obesity (BMI ≥35 kg/m²), bariatric surgery is more effective than medical therapy for achieving glycemic remission, reducing cardiovascular risk factors, and reducing all-cause mortality.
Comorbidity Management in T2DM
| Comorbidity | Goal |
|---|---|
| Blood pressure | Target <130/80 mmHg; ACE inhibitors/ARBs preferred (renal protective) |
| Dyslipidemia | Statins are first-line; LDL target <70 mg/dL in high-risk patients |
| Nephropathy | Screen for albuminuria; treat with ACEi or ARB |
| Cardiovascular disease | SGLT-2 inhibitors or GLP-1 agonists with proven CV benefit |
Sources: Goldman-Cecil Medicine, 26e; Lippincott Illustrated Reviews: Pharmacology; Textbook of Family Medicine, 9e
This is a shared conversation. Sign in to Orris to start your own chat.